Single Particle Liquid Biopsy Analysis for Disease Diagnostics

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

September 29, 2028
Response Due
Active
Status

Opportunity Overview

Liquid biopsies from patients are a non-invasive and information rich medium for diagnostics. These biological fluids contain extracellular vesicles (EVs); nano-sized membrane vesicles with a phospholipid bilayer, released by most cells whether healthy or diseased. The lipid, protein and nucleic acid composition of EVs has been found specific to their cell-type origin and therefore it may be possible to trace EVs in biological fluids to their source. Studies by the Riley group have shown that EVs secreted from the epicardium play a critical role in the human heart's regenerative capacity in response to cardiac injury (Villa del Campo et al. 2021 Cardiovasc. Res.). Therefore, if we are able to characterise the contents of EVs in biological fluids, link them back to their cellular origin (e.g. injured heart tissue) and identify their specific regenerative potential, using EVs as biomarkers can offer a unique, non-invasive liquid-biopsy-based solution for diagnosis and longitudinal monitoring of tissue regeneration including treatment response.

A key challenge is the heterogeneity of the samples which contain EVs from multiple cell types. The Stevens group has developed a novel platform called SPARTA(registered trademark) (Single Particle Automated Raman Trapping Analysis), which is now being commercialised by spin-out company SPARTA Biodiscovery Ltd. This technique offers a unique solution for analyses of EVs by utilizing automated single particle trapping with Raman spectroscopy. This means SPARTA(registered trademark) can provide high-throughput biochemical information, in the form of Raman spectral fingerprints of individual EVs, enabling us to distinguish between EV subtypes within mixtures, which would not be possible with bulk techniques. Research in the Stevens group (Penders et al. 2021 ACS Nano) has indicated a tremendous potential for sensitive and specific detection of disease vs. healthy cell derived EVs using SPARTA(registered trademark).

In close...

This is one of 1,831 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedSeptember 30, 2024
Procurement stageActive solicitation
Response dueSeptember 29, 2028
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Rotation year
Title of project: Evaluation of the quantitative accuracy and radiation dosimetry of an advanced pre-clinical multipinhole SPECT/CT theranostic imag
Discerning MCT1s role in chromatin remodelling and metabolomics changes in cancer progression
Leveraging real world data to characterise the long term impact of COVID-19
Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
Characterising the role of TEX12 in centrosome and cilia development
Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)
Iron and immunity

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.